



KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: Unit No.22 & 23, Hasti Industrial Premises Co-Op Soc Ltd, Plot No R-798, Mahape, MIDC, Navi Mumbai, Ghansoli, Thane, Rabale, Maharashtra, India, 400701.

Phone: +91-8976792931, Email: investors@june4gmp.com,

Website: www.kashyaptele-medicines.com

November 12, 2025

To
The General Manager-Listing
Corporate Relationship Department
BSE Limited, Ground Floor,
P.J. Towers, Dalal Street, Mumbai.

Scrip Code: 531960

Sub: Outcome of Meeting of Board of Directors Held on Wednesday, November 12, 2025

Ref: Disclosure under Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to above subject and in compliance with Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. **Wednesday, November 12, 2025**, has considered and approved the following: -

1. Un-Audited Financial Results (UFR) for the Second quarter and Half Year ended September 30, 2025, along with the Statutory Auditors' Limited Review Report pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. Reviewed the other business of the company.

You are requested to kindly take the same on record.

The Board Meeting commenced at 12.00 P.M. and concluded at 4.30 P.M.

Thanking you,

Yours faithfully

For Kashyap Tele-Medicines Limited

KALPESH BIPIN SHETH

Managing Director (DIN: 00405151)

Encl. as above

Independent Auditor's Review Report on unaudited standalone financial results of Kashyap Tele-Medicines Limited the quarter ended 30 September 2025 and year-to-date results for the period from 01 April 2025 to 30 September 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors of
Kashyap Tele-Medicines Limited

Introduction

1. We have reviewed the accompanying statement of unaudited standalone financial results of Kashyap Tele-Medicines Limited ('the Company') for the quarter ended 30 September 2025 and year-to-date results for the period from 01 April 2025 to 30 September 2025 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard ('Ind AS') 34 'Interim Financial Reporting' specified in section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

Scope of Review

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ('SRE') 2410 - 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India ('the ICAI'). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company's personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Shah Valera & Associates LLP

Chartered Accountants



For **Shah Valera & Associates LLP**

Chartered Accountants

Firm Registration Number: W100238



Priten B Shah

Partner

ICAI Membership No: 149028

UDIN: 25149028BMLBHH6572

Place: Mumbai

Date: 12 November 2025

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: Unit No.22 & 23, Hasti Industrial Premises Co-Op Soc Ltd, Plot No R-798, Mahape, MIDC, Navi Mumbai, Ghansoli, Thane, Rabale, Maharashtra, India, 400701

Phone: +91-8976792931, Email: investors@june4gmp.com

Website: www.kashyaptele-medicines.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPT, 2025

S.No.	Particulars	INR in Lakhs Except EPS					
		Quarter Ended			Half Year Ended		Year Ended
		30/09/2025 (Unaudited)	30/06/2025 (Unaudited)	30/09/2024 (Unaudited)	30/09/2025 (Unaudited)	30/09/2024 (Unaudited)	31/03/2025 (Audited)
I	Revenue from operations	-	-	5.50	-	11.40	19.20
II	Other Income	-	-	-	-	-	0.00
III	Total Revenue (I + II)	-	-	5.50	-	11.40	19.20
IV	Expenses						
	(a) Cost of materials consumed	-	-	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	(d) Employee benefits expense	0.60	0.11	2.54	0.71	6.32	10.81
	(e) Finance Cost	-	-	-	-	-	-
	(f) Depreciation and amortisation expense	-	-	-	-	-	-
	(g) Other expenses	5.08	2.87	2.52	7.98	4.30	8.40
	Total expenses	5.68	2.98	5.06	8.69	10.62	19.21
V	Profit / (Loss) Before Tax (III- IV)	(5.68)	(2.98)	0.44	(8.69)	0.78	(0.01)
VI	Tax Expense :-						
	(a) Current tax	-	-	-	-	-	-
	(b) Tax relating to previous year	-	-	-	-	-	0.02
	Total Tax Expense	-	-	-	-	-	0.02
VII	Profit / (Loss) for the period (V - IV)	(5.68)	(2.98)	0.44	(8.69)	0.78	(0.03)
VIII	Other Comprehensive Income						
	A. Items that will be/will not be reclassified to profit and loss	-	-	-	-	-	-
	B. Income tax relating to items that will be / will not be reclassified to profit and loss	-	-	-	-	-	-
	Total comprehensive income for the period (VII+VIII)	(5.68)	(2.98)	0.44	(8.69)	0.78	(0.03)
IX	Paid-up Equity Share Capital (Face Value of Rs. 1/- each)	477.22	477.22	477.22	477.22	477.22	477.22
X	Other Equity excluding revaluation reserves	(421.24)	(416.26)		(421.97)		(413.27)
XXII	Earnings per equity share:						
	Basic and diluted	(0.012)	(0.006)	0.001	(0.018)	0.002	(0.000)

*Notes Enclosed

Place : Mumbai

Date : 12/11/2025



For and on behalf of Board of Directors of
Kashyap Tele - Medicines Limited

KALPESH BIPIN SHETH
Managing Director
DIN: 00405151

Notes to Unaudited Financial Results for the quarter and half year ended 30th Sept, 2025:

1	The above Unaudited Financial Results of the Company for the quarter and half year ended 30th September, 2025 have been reviewed & recommended by the Audit Committee and approved by the Board of Directors in the Meeting held on 12th November, 2025. The same have been subjected to Limited Review by the Statutory Auditors.
2	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices & policies to the extent applicable.
3	The Company is engaged in single segment i.e. 'Software Sales', therefore has only one reportable segment in accordance with Ind AS 108 'operating segments'.
4	Pursuant to compliance of SEBI notification No. SEBI/LAD-NRO/GN/2018/1 dated 9th May, 2018, a statement of Cash Flow for the Half year ended 30th September, 2025 has also been submitted by way of a note as enclosed herewith as Annexure-A to the said notes to unaudited Financial Results & Statement of Assets & Liabilities.
5	A Copy of the aforesaid financial results is also available on the website of BSE Limited (www.bseindia.com) and on the website of the Company (www.kashyaptele-medicines.com).
6	Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.

Date : 12/11/2025

Place : Mumbai



**For and on behalf of Board of Directors of
For Kashyap Tele - Medicines Limited**



KALPESH BIPIN SHETH
Managing Director
DIN: 00405151

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: Unit No.22 & 23, Hasti Industrial Premises Co-Op Soc Ltd, Plot No R-798, Mahape, MIDC, Navi Mumbai, Ghansoli, Thane, Rabale, Maharashtra, India, 400701

Phone: +91-8976792931, Email: investors@june4gmp.com

Website: www.kashyaptele-medicines.com

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2025

INR in Lakhs

Particulars	As at 30/09/2025 (Unaudited)	As at 31/03/2025(Audited)
ASSETS		
I Non-Current Assets		
(a) Property, Plant and Equipment	-	-
(b) Capital work in progress	-	-
(c) Financial Assets	-	-
(i) Investments	-	-
(ii) Other Financial Assets	0.34	0.34
(d) Other Non-Current Assets	-	65.43
	0.34	65.77
II Current Assets		
(a) Inventories	-	-
(b) Financial Assets	-	-
(i) Trade Receivables	-	-
(ii) Cash and Cash Equivalents	61.37	0.37
(iii) Investments	-	-
(iv) Loans	-	-
(c) Current Tax Assets (Net)	0.16	0.16
(d) Other current assets	2.38	-
	63.91	0.53
TOTAL ASSETS	64.25	66.30
EQUITY AND LIABILITIES		
I Equity		
(a) Share Capital	477.22	477.22
(b) Other Equity	(421.97)	(413.27)
	55.25	63.95
II Non Current Liabilities		
(a) Financial liabilities		
(i) Long term borrowings	-	-
(b) Deferred tax liabilities (net)	-	-
(c) Other long term liabilities	-	-
III Current Liabilities		
(a) Financial liabilities		
(i) Short term borrowings	-	-
(ii) Trade Payables	-	-
Total Outstanding dues of micro enterprises and small enterprises	-	-
Total Outstanding dues of others	-	-
(iii) Other Financial liabilities	2.61	2.35
(b) Other Current Liabilities	6.38	-
(c) Short-Term Provisions	-	-
(d) Income tax liabilities	-	-
	8.99	2.35
TOTAL EQUITY AND LIABILITIES	64.25	66.30

*Notes Enclosed

Place : Mumbai
Date : 12/11/2025



For and on behalf of Board of Directors of
For, Kashyap Tele - Medicines Limited

Kalpesh Bipin Sheth
Managing Director
DIN: 00405151

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: Unit No.22 & 23, Hasti Industrial Premises Co-Op Soc Ltd, Plot No R-798, Mahape, MIDC, Navi Mumbai,
Ghansoli, Thane, Rabale, Maharashtra, India, 400701

Phone: +91-8976792931, Email: investors@june4gmp.com

Website: www.kashyaptele-medicines.com

Cash Flow Statement for the half year ended 30th September 2025

		INR in Lakhs	
Particulars		For the half year ended 30/09/2025	For the half year ended 30/09/2024
A	Cash flow from operating activities:		
	Profit/(Loss) before tax	(8.69)	0.78
	Operating profit before working capital changes	(8.69)	0.78
	Adjustments for changes in working capital :		
	Change in trade receivables	-	(4.85)
	Movement in other assets	(2.38)	
	Decrease/(Increase) in inventories		
	Decrease/ in current investments		
	(Increase) in financial assets		
	Change in other receivables	65.43	(2.30)
	Change in Current Liabilities & other payables	6.64	(2.30)
	Cash flow from/ (used in) operations	61.00	(8.67)
	Income taxes paid	-	(0.04)
	Net cash flow from/(used in) operating activities	61.00	(8.63)
B	Cash flow from investing activities:		
	Interest received	-	-
	Net cash (used in)/flow from investing activities	-	-
C	Cash flow from financing activities:		
	Interest paid		
	Net cash (used in)/flow from financing activities:	-	-
D	Net increase in cash and cash equivalents (A+B+C)	61.00	(8.63)
	Cash and cash equivalents at the beginning of the period	0.37	8.97
	Cash and cash equivalents at the end of the period	61.37	0.34

Place : Mumbai
Date : 12/11/2025For and on behalf of Board of Directors of
For Kashyap Tele - Medicines LimitedKalpesh Bipin Sheth
Managing Director
DIN: 00405151